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Abstract
Methods Ten consecutive children (0–18 years) who
underwent primary tumor resection for a spinal ependymoma
between 1980 and 2011 were included in this retrospective
study. Gross motor function and activities of daily life were
scored according to the Barthel Index.
Conclusion Three out of six pediatric patients treated for spinal
myxopapillary ependymoma are disease-free after 11 to 33 years
of follow-up. The other three have progressive disease, after
relapses occurring after 4.5, 7, and 20 years, respectively. One
out of two patients with grade II ependymoma had progressive
disease from 10 years after initial surgery but is in full-time work
in spite of widespread metastatic disease after 32 years. One of
the two children with grade III tumor died from progressive
disease 17 years from primary diagnosis, while the last one is
tumor-free after 19 years. The quality of life is good for three of
the four patients with widespread disease, and they are managed
conservatively aiming at symptomatic treatment intervention if
necessary. We strongly advocate lifelong follow-up for children
treated for spinal ependymomas.
Keywords Pediatric spinal ependymomas .Myxopapillary
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Ependymoma is the third most common central nervous sys-
tem (CNS) tumor in childhood, most often located
intracranially, with a predilection for the posterior fossa [15,
18, 28]. The handling of children with such tumors is chal-
lenging because of a marked tendency of local recurrence as
well as disseminated disease in some patients. Postoperative
radiotherapy has therefore often been offered to patients over
the age of 3, and in later years, chemotherapy has also been
given to pediatric patients with ependymoma [1, 3]. Spinal
ependymomas are exceedingly rare in children and adoles-
cents in contrast to adults. In adults, a spinal localization is the
most common site of ependymoma and long-term results are
very good, even with surgical resection alone [14, 31].
Herein, we summarize our institutional experience of spi-
nal pediatric ependymoma presenting the ten consecutive
pediatric cases treated between 1980 and 2011.
Methods
We retrospectively analyzed a consecutive cohort consisting
of ten patients aged 18 years or younger who underwent
primary resection for a spinal ependymoma during the years
1980 to 2011 in the Department of Neurosurgery, Oslo Uni-
versity Hospital, Norway.
The cases were collected by reviewing surgical protocols of
the relevant time period identifying pediatric ependymoma
cases. The histological specimens were reviewed for all 10
cases.
The case record data included sex, age at the time of
primary tumor resection, detailed information on repeat oper-
ations, and adjuvant treatment.
Scholastic outcome was simplified into normal versus spe-
cial schooling, and employment attendance into open, shel-
tered, or no work.
The Barthel Index score is a well-established and validated
scale using ten variables to measure performance in basic
activities of daily living (ADL) primarily related to personal
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care and mobility [17]. Scores range from 0 to 100 and a
higher score denotes greater independence. The purpose of
reporting the Barthel Index was to assess functional status and




Table 1 shows that six children (five boys) had a
myxopapillary ependymoma. Two children had ependymoma
grade II and two had anaplastic ependymoma, grade III. The
sex and age of the child at primary surgery are listed in
Table 1.
Most patients presented with severe low back pain and
varying degrees of paraparesis; in one case, also severe
incontinence. The diagnosis of an intraspinal tumor was done
by myelography (before 1987) or MRI (from 1987), and from
1987, repeat MRI scans were introduced in the follow-up
program. All tumors were intradurally located distal to the
vertebra T10 with affection of the conus and/or cauda equina
at the primary presentation.
Pathology
The histological examination revealed myxopapillary
ependymoma (WHO grade I) in six patients. Two children
were diagnosed with ependymomaWHO grade II and the last
two patients had an anaplastic tumor, WHO grade III.
Primary treatment
All patients had primary surgery. Whenever possible, gross
total resection (GTR) was the aim of the surgical procedure,
Table 1 Summary of clinical data for the ten patients
Patient Sex/age Histology Localization Radicality Radiotherapy Recurrence Follow-up Status
1 M/1.5 Myxopapillary WHO 1 T10–L1 Yes No No 27 years NED
2 M/7 Myxopapillary WHO 1 L1–L3 Yes No No 11.5 years NED
3 M/12 Myxopapillary WHO 1 L2–S3 No 54 Gy
T2–5 No 54 Gy Yes, 7 years 33 years AWD
4 F/15 Myxopapillary WHO 1 L2 No 52 Gy
Local No Yes, 20 years
Local No Yes, 22 years
Local No Yes, 23 years
Paraspinal Yes, 24 years
Paraspinal Yes, 25 years
Pulm. met Yes, 31 years 32 years AWD
5 M/16 Myxopapillary WHO 1 L3 Yes No
L3–S5 No 54 Gy Yes, 4.5 years 6 years AWD
6 M/18 Myxopapillary WHO 1 L2 Yes No No 13 years NED
7 M/9 Ependymoma WHO 2 Cauda eq. No 44 Gy No 33 years NED
8 F/15 Ependymoma WHO 2 L2 Yes No
Suprasellar No Yes, 10 years
L2–L3 51 Gy Yes, 14.5 years
Multiple intra-
Cranial No surgery Yes, 32 years 32 years AWD
9 M/7 Anaplastic WHO 3 L1–S4 Yes No
Anaplastic WHO 3 Local No 54 Gy Yes, 3,5 years
Local No Yes, 13 years
Local No Yes, 14 years
Local No Yes, 15 years
Paraspinal No Yes, 16 years
Paraspinal No Yes, 17 years 17 years DOD
10 F/8 Anaplastic WHO 3 L2–L3 No 54 Gy No 19 years NED
DOD dead of disease, AWD alive with disease, NED no evidence of disease
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and the degree of resection was evaluated by the surgeon in
the first part of the period and in later years also by immediate
postoperative MRI scans. The resection was considered com-
plete in six children (Table 1.) All ten patients recovered
rapidly after surgery. All four children with incomplete resec-
tion were given postoperative local radiotherapy with doses
ranging from 44 Gy (one patient) to 51–54 Gy. No patient
received systemic antineoplastic treatment.
Recurrent disease in children with myxopapillary
ependymoma
Local tumor recurrence was observed in three of the six
patients, after 4.5, 7, and 20 years, respectively, from primary
treatment. One of these (Table 1, patient 5) patients with GTR
(and no initial radiotherapy) experienced local recurrence after
4.5 years. He underwent repeat surgery and radiotherapy and
has later on received extended spinal radiotherapy due to
disease in progress. Furthermore, two patients with non-
GTR who did receive primary radiotherapy have experienced
recurrent disease (Table 1).
In one patient with recurrence after 7 years (Table 1, patient
3), widespread dissemination to the cervicothoracic spinal
canal was diagnosed synchronously to local progression.
The clinical presentation at the time of recurrence was a high
thoracic transverse myelopathy, and the patient had a tumor
resection at the level of T2–5, followed by adjuvant radiother-
apy above the primary lumbosacral level which had been
irradiated in the primary situation. He was in full-time work
as a blacksmith until a couple of years ago but is now, 26 years
following his recurrence, outside the labor market because of
severe back pain. A recent MRI has demonstrated multiple
tumor manifestations from C6 and distally in the spinal canal.
Clinically, however, in spite of his severe back pain, he is
neurologically remarkably well, with preserved sexual, blad-
der, and bowel function.
The only girl in this group (patient 4) underwent tumor
resection at the L2 level and classified as non-GTR had
received 52 Gy locally. Twenty years later, she came back
with local recurrence. During the subsequent 11 years she has
undergone five resections for intraspinal or paraspinal tumor
progression and 31 years after initial treatment also resection
of two pulmonary metastases from her myxopapillary
ependymoma. She has also had oncological treatment with
chemotherapy and further radiotherapy.
Recurrent disease in children with ependymoma grade II
and III
One of the two patients with grade II tumor is disease-free
with 33 years follow-up. The other had recurrence and it is a
bit surprising that the one with recurrence was a GTR primar-
ily, whereas in the non-GTR patient, the disease did not recur.
The latter had radiotherapy up front. The same peculiar situ-
ation was found for grade III tumors; the one with GTR had
recurrence, whereas the one with non-GTR and radiotherapy
did not experience regrowth of the tumor.
The grade II patient with recurrence came with clinical
symptoms of a suprasellar tumor 10 years after primary resec-
tion (GTR) of a grade II ependymoma at the L2 level at the age
of 15 years (Table 1, patient 8). After resection (GTR) of the
intracranial grade II ependymoma, further follow-up disclosed
local recurrence at the level of L2/3 5 years later. She received
radiotherapy (51 Gy) at the lumbar level. Today, 32 years after
initial treatment, she has multiple intraventricular manifesta-
tions of her disease, but with sparse clinical symptoms.
One of the children treated for grade III tumor is disease-
free 19 years after a non-GTR resection followed by local
radiotherapy (54 Gy). The other grade III patient did not
receive initial radiotherapy after a GTR resection. He
succumbed to his neoplastic disease 17 years after initial
surgery; he had a total of seven tumor resections (Table 1,
patient 9).
Motor function and activities of daily life
Gross motor function and management of the activities
of daily life is good in all the nine survivors. In terms
of the Barthel Index, the score is 100 in eight and 80 in
the last one.
School, education, and work
One of the nine survivors has a current age below 20
(18 years) and follows a regular school program. The remain-
ing eight survivors are aged 22–47 years. One is a student and
six are in regular work, whereas the last two are outside the
labor market.
Discussion
Spinal ependymomas are exceedingly rare in the pedi-
atric population when compared to adults, where a
spinal location is the most frequent localization of
ependymoma [4, 9, 20, 31]. In a recent publication from
our institution, 86 consecutive spinal ependymoma cases
diagnosed between 1987 and 2007 were reviewed. The
results were good with a 10-year overall survival (OS)
of 91 % and a progression-free survival (PFS) of 75 %.
Only two of these cases were children [14].
In a review article, Oh and coworkers found that the
prognosis for adults treated for spinal cord ependymoma
varied with tumor location within the spinal canal; a better
prognosis was found for patients with tumors in the upper
spinal cord than for patients with a distal tumor location [23].
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All WHO grades were included, also myxopapillary tumors
(grade I).
In another review performed by the same authors, a similar
trend was found in children; a better prognosis for individuals
with tumors in the upper spinal canal compared to a distal
tumor location [24]. In this report, however, myxopapillary
ependymomas were excluded. Furthermore, the vast majority
of pediatric spinal ependymomas occur in the distal spinal
canal [32].
A number of authors have pointed out that the long-term
prognosis for pediatric spinal ependymoma cases may be
inferior compared to adult cases [6, 11, 13, 19, 32].
Because of the limited numbers of such cases in the
English literature, as well as variability of histological
grades, different treatment strategies have been under-
taken and the optimal treatment schedules have not been
firmly established [6].
Although total surgical resection has been shown to im-
prove long-term results [30] and reduce the need for postop-
erative radiotherapy at least in grade I and II tumors, some
authors have advocated local postoperative irradiation follow-
ing incomplete resection in all children with anaplastic (grade
III) lesions irrespective of the completeness of resection [3,
13].
McGuire and coworkers do not, based on compiled data
from 55 children, recommend postoperative radiotherapy for
pediatric spinal ependymomas. This is in contrast to their
recommendations for pediatric posterior fossa ependymomas
where they show an improved 5-year survival with postoper-
ative irradiation after surgery based on analysis of 193 cases
treated between 1973 and 2003 [19].
Gross total resection has been shown to reduce the risk for
recurrence and increase progression-free survival (PFS) [5, 7,
30]. In cases with involvement of the conus, the likelihood of
complete resection is reduced or implies an increased risk of
postoperative morbidity [2].
Several authors state that the myxopapillary tumor of the
spinal canal appears to have a marked tendency to recur and
metastasize [6, 11, 13, 27]. Therefore, many authors advocate
postoperative radiotherapy [8, 25, 26].
Pica et al. analyzed 85 cases of spinal myxopapillary
ependymomas of all ages treated between 1970 and 2007
and found significantly improved 5-year PFS with concomi-
tant local radiotherapy. Their series appears to include mainly
adult cases, with a median age of 37 years. Median follow-up
was only 60 months [29].
Al-Halabi et al. advocate routine postoperative local irra-
diation for pediatric spinal myxopapillary ependymomas,
based on a study of seven cases treated between 1985 and
2008 [3]. Again, the follow-up period is relatively short, with
a median of 78 months.
Based on this, it is evident that long-term follow-up over
the decades has not previously been reported and most
published series are small. Compiled data from several centers
have been published for 85 children operated between 1970
and 2007 for spinal myxopapillary ependymoma; however,
with short follow-up times (see above) [29].
Even in adults, very long-term results are absent. Gomez
and coworkers report high failure rates in 37 patients treated
between 1955 and 2001, but the median long-term follow-up
was 121 months [13].
The present series include all children treated for a spinal
ependymoma in our institution in a time period of 31 years.
They represent 0.6 % of all children and adolescents treated
for a CNS tumor in the same time period and 20 % of the
pediatric ependymomas. There was no surgical mortality in
this series, and the observed long-term survival is very
encouraging.
Widespread dissemination within the spinal canal and even
intracranially from spinal ependymoma has been reported
several times [11, 21]. Although intracranial spread from a
spinal ependymoma has been published previously, it seems
to be very unusual. Such single Norwegian pediatric case was
published in 1980; a 12-year-old boy who deceased from
intracranial tumor dissemination 6.5 years after treatment of
the primary spinal ependymoma [21].
Paraspinal progressive disease and even metastatic disease
is also well known, although rare [10, 12, 16, 22].
Fassett et al. reported intracranial manifestation in four out
of five pediatric cases with spinal ependymoma treated inside
an 11-year-period [11]. They therefore advocate craniospinal
MRI of all pediatric ependymoma cases. We agree with Ste-
phen and coworkers, who advocate prolonged follow-up reg-
imens including MRI for pediatric cases with spinal
ependymoma, especially patients with myxopapillary tumors
[32]. Our series demonstrate recurrent disease also in patients
with grade II or III tumors.
We consider our small series of ten patients representative,
since it is consecutive and includes all children operated for a
spinal ependymoma in a period of 31 years. The recurrence
rate is high (50 %) and it should be noted that two of the
recurrences were diagnosed as late as 14 and 20 years follow-
ing the time of primary diagnosis.
It was the reappearance of severe clinical symptoms (pain
and/or paraparesis) which led to the diagnosis of recurrence.
MRI was used for diagnosis and repeat surgery was performed
(in all but one patient) after local recurrence had been demon-
strated. All five have undergone local radiotherapy. Four of
them now have more widespread tumor manifestations in the
spinal canal but for the time being have a relatively stable or
very slowly progressive situation with respect to their neo-
plastic disease in the spinal canal. For one of them, this is the
situation 26 years after the second surgery and further radio-
therapy for progressive disease in the upper thoracic level,
7 years after initial surgery and postoperative radiotherapy in
the lumbosacral region.
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One patient has been operated for intracranial
ependymoma as well as for a local recurrence. In this patient,
the widespread intracranial manifestations appear indolent
after further 22 years of follow-up and she is in full-time work
32 years after the primary surgery.
Our recurrence rate of 50 % is high and above the rate in
many other reported small series and even in compiled data
from many series. Because of the relatively short follow-up in
most series, as well as the late recurrences we have observed
in the present study, it is possible that lower rates are merely a
consequence of too short follow-up. Furthermore, the intrigu-
ing data presented by Fassett and coworkers, with simulta-
neous diagnosis of intracranial ependymoma lesions in four
out of five children at the time of primary diagnosis of a spinal
myxopapillary ependymoma, open another question [11]. Is it
obvious that further manifestations found in the spinal canal or
intracranially in the long-term follow-up are metastatic disease
from the primary ependymoma in the lumbosacral region?
Since we do not have completeMRI data, especially for the
patients operated 30 years ago, we can only conclude that
consequent implementation of craniospinal MRI over time
would be very valuable in such patients.
Because of the puzzling indolent clinical situation observed
in at least two of the patients with widespread disease and
more than 30 years follow-up seen in this series, it is evident
that it is difficult to make treatment decisions for this patient
group. Furthermore, very long-term follow-up with MRI
seems indicated in these patients.
Conclusion
Three out of six children treated for distal spinal
myxopapillary ependymoma have not experienced recurrent
disease and are free of tumor as evaluated by MRI after 11 to
33 years of follow-up. Three children had surgery for local
recurrence and/or distant spinal disease from 4.5 to 20 years
after the initial surgery. The patient with very late recurrence
has also had multiple surgeries for paraspinal progression, as
well as for metastatic disease to the lung, but is still alive after
32 years.
In one of the two patients treated for grade II tumor,
widespread intracranial and distant spinal disease have been
evident for 18 years, but the patient is in full-time work at the
age of 48; 32 years after the initial treatment.
One of two patients with grade III tumor died after
17 years due to progressive paraspinal manifestations.
The last one is tumor-free after 19 years follow-up.
GTR may cure children with distal spinal ependymoma,
but does not prevent recurrence in all cases. Incomplete
resection followed by local radiotherapy can also give
excellent long-term results, but recurrence may appear
after many years. Long-term follow-up including MRI
for decades is therefore necessary.
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